Skip to main content

Table 3 Summary of safety data

From: A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]

 

Placebo

Etoricoxib 90 mg

Naproxen 1000 mg

 

(N = 357)

(N = 353)

(N = 181)

 

n (%)

n (%)

n (%)

Number of patients:

   

   With any drug-related clinical adverse event

55 (15.4)

82 (23.2)

35 (19.3)

   With any serious clinical adverse event

3 (0.8)

7 (2.0)

3 (1.7)

   Discontinued due to clinical adverse event

6 (1.7)

9 (2.5)

5 (2.8)

  1. p < 0.05 vs placebo. 
  2. Serious adverse events were: placebo (3 patients) – thrombophlebitis, atrial fibrillation, and pneumothorax; etoricoxib (7 patients) – pulmonary embolism, angina pectoris, thyroid cancer, duodenal ulcer, hip pain, femoral fracture, and traumatic arthropathy plus corneal degeneration (in the same patient); naproxen (3 patients) – hypertension, intervertebral disc displacement, and retinal detachment.